629 related articles for article (PubMed ID: 19229819)
41. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
[TBL] [Abstract][Full Text] [Related]
42. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
Mittman N; Desiraju B; Meyer KB; Chattopadhyay J; Avram MM
Kidney Int Suppl; 2010 Aug; (117):S33-6. PubMed ID: 20671742
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
Večerić-Haler Ž; Romozi K; Antonič M; Benedik M; Ponikvar JB; Ponikvar R; Knap B
Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912
[TBL] [Abstract][Full Text] [Related]
44. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
[TBL] [Abstract][Full Text] [Related]
45. Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.
Coronel F; Rodríguez-Cubillo B; Cigarrán S; Gomis A
Adv Perit Dial; 2011; 27():130-3. PubMed ID: 22073844
[TBL] [Abstract][Full Text] [Related]
46. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.
Cozzolino M; Galassi A; Gallieni M; Brancaccio D
Curr Vasc Pharmacol; 2008 Apr; 6(2):148-53. PubMed ID: 18393917
[TBL] [Abstract][Full Text] [Related]
47. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol.
Moe SM; Zekonis M; Harezlak J; Ambrosius WT; Gassensmith CM; Murphy CL; Russell RR; Batiuk TD
Am J Kidney Dis; 2001 Oct; 38(4):792-802. PubMed ID: 11576883
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective.
Menezes FG; Abreu RM; Itria A
J Bras Nefrol; 2016; 38(3):313-319. PubMed ID: 27737389
[TBL] [Abstract][Full Text] [Related]
49. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
50. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
51. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients.
Sezer S; Tutal E; Bal Z; Uyar ME; Bal U; Cakir U; Acar NO; Haberal M
Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898
[TBL] [Abstract][Full Text] [Related]
52. Differential effects of vitamin D analogs on vascular calcification.
Cardús A; Panizo S; Parisi E; Fernandez E; Valdivielso JM
J Bone Miner Res; 2007 Jun; 22(6):860-6. PubMed ID: 17352647
[TBL] [Abstract][Full Text] [Related]
53. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
[TBL] [Abstract][Full Text] [Related]
54. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
55. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
[TBL] [Abstract][Full Text] [Related]
56. Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients.
Lomonte C; Martino R; Selvaggiolo M; Bona RM; Cazzato F; Milano R; Chiarulli G; Basile C
J Nephrol; 2003; 16(5):716-20. PubMed ID: 14733419
[TBL] [Abstract][Full Text] [Related]
57. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
Martin KJ; González EA; Gellens M; Hamm LL; Abboud H; Lindberg J
J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664
[TBL] [Abstract][Full Text] [Related]
58. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
59. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study.
Lezaic V; Pejanovic S; Kostic S; Pljesa S; Dimkovic N; Komadina L; Jovanovic D; Marinkovic J; Djukanovic L
Ther Apher Dial; 2007 Apr; 11(2):121-30. PubMed ID: 17381533
[TBL] [Abstract][Full Text] [Related]
60. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]